Inavolisib

Inavolisib
Clinical data
Pronunciation	inn-uh-voh-LIS-ib
Routes of; administration	Oral
Pharmacokinetic data
Elimination half-life	16–18 hours
Identifiers
	IUPAC name (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide;
CAS Number	2060571-02-8;
PubChem CID	124173720;
ChEMBL	ChEMBL4650215;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C18H19F2N5O4
Molar mass	407.4 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C(=O)N)NC1=CC2=C(C=C1)C3=NC(=CN3CCO2)N4C(COC4=O)C(F)F;
	InChI InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33); Key:SGEUNORSOZVTOL-CABZTGNLSA-N;

Inavolisib (development code: GDC-0077) is an experimental cancer medicine developed by Genentech. Inavolisib is a small molecule inhibitor targeting the p110α protein product of the phosphoinositide 3-kinase gene, PIK3CA.^[1]^[2]

Inavolisib is currently in a variety of clinical trials for cancers with mutations in the PIK3CA gene.^[3]

References

↑ PubChem. "Gdc-0077". pubchem.ncbi.nlm.nih.gov. Retrieved 2022-01-31.
↑ Song, Kyung W.; Edgar, Kyle A.; Hanan, Emily J.; Hafner, Marc; Oeh, Jason; Merchant, Mark; Sampath, Deepak; Nannini, Michelle A.; Hong, Rebecca; Phu, Lilian; Forrest, William F. (2021-09-20). "RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy". Cancer Discovery. 12 (1): 204–219. doi:10.1158/2159-8290.cd-21-0072. ISSN 2159-8274.
↑ "Search of: GDC-0077 inavolisib - List Results - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2022-02-01.

Category:Drugs Category:Phosphoinositide 3-kinase inhibitors Category:Antineoplastic drugs Category:Breast cancer

This article "Inavolisib" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Inavolisib. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

This page exists already on Wikipedia.

[1] PubChem. "Gdc-0077". pubchem.ncbi.nlm.nih.gov. Retrieved 2022-01-31.

[2] Song, Kyung W.; Edgar, Kyle A.; Hanan, Emily J.; Hafner, Marc; Oeh, Jason; Merchant, Mark; Sampath, Deepak; Nannini, Michelle A.; Hong, Rebecca; Phu, Lilian; Forrest, William F. (2021-09-20). "RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy". Cancer Discovery. 12 (1): 204–219. doi:10.1158/2159-8290.cd-21-0072. ISSN 2159-8274.

[3] "Search of: GDC-0077 inavolisib - List Results - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2022-02-01.

[1]

[2]

[3]

Clinical data
Pronunciation	inn-uh-voh-LIS-ib
Routes of administration	Oral
Pharmacokinetic data
Elimination half-life	16–18 hours
Identifiers
IUPAC name (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide
CAS Number	2060571-02-8
PubChem CID	124173720
ChEMBL	ChEMBL4650215
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C18H19F2N5O4
Molar mass	407.4 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC(C(=O)N)NC1=CC2=C(C=C1)C3=NC(=CN3CCO2)N4C(COC4=O)C(F)F
InChI InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33) Key:SGEUNORSOZVTOL-CABZTGNLSA-N

Inavolisib

References

📰 Article(s) of the same category(ies)[edit]